Nyrada Inc – Phase I Clinical Trial Dosing Update #3
Highlights: •Safety Review Committee (SRC) for Nyrada’s Phase I clinical trial has considered cumulative safety and pharmacokinetic data, including from… Read more
NYR-BI03 Extends Cardioprotection to Arrhythmia Control
Highlights: •Preclinical study demonstrates NYR-BI03 provides strong cardioprotection when administered as a short-duration intravenous infusion following myocardial infarction (heart attack)…. Read more
Nyrada Inc – Phase I Clinical Trial Dosing Update #2
Highlights: •Nyrada’s Phase I clinical trial Safety Review Committee (SRC) has considered cumulative safety and pharmacokinetic data, including from the… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Development of lead drug candidate NYR-BI03 continues: -Phase I clinical trial commenced with first cohort dosing completed and second… Read more
Nyrada Inc -Phase I Clinical Trial Dosing Update #1
Highlights: •Nyrada’s Phase I clinical trial Safety Review Committee (SRC) has considered safety and pharmacokinetic data from first dosed cohort…. Read more
Nyrada Inc Significant Neuroprotection Achieved in Collaborative Traumatic Brain Injury Study
Highlights: •Lead drug candidate NYR-BI03 shows strong neuroprotective efficacy in a penetrating traumatic brain injury study, conducted in collaboration with… Read more
First Cohort Dosed in Nyrada’s Phase I Clinical Trial
Highlights: •First cohort of participants dosed in Nyrada’s Phase I first-in-human clinical trial. •Six participants received NYR-BI03 while two participants… Read more
Nyrada Commences Phase I Clinical Trial Recruitment
Highlights: •Participant recruitment has now commenced in Nyrada’s Phase Ia first-in-human clinical trial. •Phase I trial designed to assess safety,… Read more
Nyrada Inc – 2025 EGM Letter to Shareholders, Notice of Meeting and Proxy
Nyrada Inc (ASX:NYR) (“Nyrada” or “Company”), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC)… Read more